Jonathan Mauricio Muñoz-Cabrera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonathan Mauricio Muñoz-Cabrera has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adrián Gabriel Sandoval-Hernández
Grupo de Muerte Celular, Instituto de Genética, Universidad Nacional de Colombia, Sede Bogotá, Carrera 30 No 45-03, Bogotá 111321, Colombia
1 shared publication - Alejandro Múnera
Behavioral Neurophysiology Laboratory, Universidad Nacional de Colombia, Bogotá, Colombia; Physiological Sciences Department, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
1 shared publication Andrea Niño
Grupo de Muerte Celular, Instituto de Genética, Universidad Nacional de Colombia, Bogotá, Colombia
1 shared publication- Angie Bustos-Rangel
Grupo de Muerte Celular, Instituto de Genética, Universidad Nacional de Colombia, Bogotá, Colombia
1 shared publication - Gloria Patricia Cardona-Gómez
Neuroscience Group of Antioquia, Cellular and Molecular Neurobiology Area, School of Medicine, SIU, University of Antioquia, Medellín, Colombia
1 shared publication - Gonzalo Arboleda
Departamento de Patologia, Instituto de Genetica, Universidad Nacional de Colombia, Carrera 30 No. 45-03, Ciudad Universitaria, Bogota, Colombia
1 shared publication
Latest Publications
- Open Access
- 9 October 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (10) , e0223578
Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer´s disease
Bexarotene, a retinoid X receptor agonist, improves cognition in murine models of Alzheimer’s disease (AD). This study evaluated the effects of bexarotene on pathological and electrophysiological changes in very old triple transgenic AD mice (3xTg-AD mice). 24-month-old 3xTg-AD mice were treated with bexarotene (100 mg/kg/day for 30 days). The Morris water maze was used to evaluate spatial memory; immunofluorescence and confocal microscopy were used to evaluate pathological changes; and in vivo electrophysiological recordings were used to evaluate basal transmission and plasticity in the commissural CA3-CA1 pathway. In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity. These results indicate that bexarotene-induced improvement in cognition is due to multiple changes that contribute to recovery of synaptic plasticity.
- 9 October 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (10) , e0223578
Open AccessBexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer´s disease
Bexarotene, a retinoid X receptor agonist, improves cognition in murine models of Alzheimer’s disease (AD). This study evaluated the effects of bexarotene on pathological and electrophysiological changes in very old triple transgenic AD mice (3xTg-AD mice). 24-month-old 3xTg-AD mice were treated with bexarotene (100 mg/kg/day for 30 days). The Morris water maze was used to evaluate spatial memory; immunofluorescence and confocal microscopy were used to evaluate pathological changes; and in vivo electrophysiological recordings were used to evaluate basal transmission and plasticity in the commissural CA3-CA1 pathway. In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity. These results indicate that bexarotene-induced improvement in cognition is due to multiple changes that contribute to recovery of synaptic plasticity.